We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Generic drugmakers already battling each other for market share could face a new and growing competitor for their generic products — the brand firms themselves.
The state of Illinois is about to introduce a prescription drug importation program that goes far beyond anything any other state or municipality has so far attempted.
With Teva acquiring a generic drugmaker in Italy and Sandoz buying a generic injectables firm in Canada, the two largest generic firms have increased their footprints on both sides of the Atlantic.
The U.S.-Australia free trade agreement (FTA), already ratified by both countries, could potentially be jeopardized by late amendments intended to protect Australia’s low-cost Pharmaceutical Benefits Scheme (PBS).
The state of Illinois is about to introduce a prescription drug importation program that goes far beyond anything any other state or municipality has so far attempted.
Despite sweeping new patent rules implemented last year to better balance the competition between brand and generic drugmakers, generic firms say the brand firm practice of making deals with generic firms to market authorized generic products is a threat to the industry.
An Aug. 3 company regulatory filing reveals that New York state’s attorney general has asked Johnson & Johnson (J&J) for documents pertaining to the marketing, off-label sales and clinical trials of five of its drug products.
The brand industry is urging the FDA to strengthen standards for FDC HIV/AIDS drugs, even as the FDA moves forward with approving the first once-daily fixed-dose combination (FDC) products and a leading generic FDC AIDS drug producer faces concerns about its products’ bioequivalency standards.
The U.S. should repeal its ban on the importation of Rx drugs and allow pharmaceutical companies and foreign countries to work out on their own what the latter will pay for U.S. patented medicines, according to a senior scholar at the libertarian Cato Institute.
Drugmaker Cephalon has granted generic firm Barr Pharmaceutical a license to manufacture and market a generic version of Cephalon’s cancer pain treatment Actiq, Barr said.